Vivos Therapeutics
VVOS
20 hedge funds and large institutions have $2M invested in Vivos Therapeutics in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.
377% more capital inflows, than outflows
Capital inflows: $1.01M | Capital outflows: $211K
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
4.51% more ownership
Funds ownership: 5.14% → 9.65% (+4.5%)
13% less funds holding
Funds holding: 23 → 20 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Anson Funds Management
Dallas,
Texas
|
+$809K |
| 2 |
Cutter & Co Brokerage
Ballwin,
Missouri
|
+$127K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$53.5K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$16.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$65.2K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$53.5K |
| 3 |
Two Sigma Investments
New York
|
-$53.5K |
| 4 |
Millennium Management
New York
|
-$31.3K |
| 5 |
Tower Research Capital (TRC)
New York
|
-$5.01K |
VVOS Hedge Fund Activity: Q4 2024 in Review
20 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q4 2024, worth a combined $2M — up 218% from $631K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of VVOS and 2 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $809K. The largest seller was OMERS Administration Corp, exiting entirely with an estimated $65.2K sold.
- 20 institutional investors held Vivos Therapeutics (VVOS) as of Q4 2024, down from 23 in Q3 2024.
- Funds reported $2M of Vivos Therapeutics stock for Q4 2024, up 218% quarter-over-quarter.
- 2 funds opened new Vivos Therapeutics positions in Q4 2024 and 5 closed out, a net change of -3 holders.
- The largest Vivos Therapeutics buyer in Q4 2024 was Anson Funds Management, an estimated $809K added.
- The largest Vivos Therapeutics seller in Q4 2024 was OMERS Administration Corp, an estimated $65.2K sold.
Based on aggregated 13F filings for Q4 2024.